Immune Design Corp. (NASDAQ:IMDZ) dropped 1.1% during mid-day trading on Monday . The stock traded as low as $5.10 and last traded at $5.15. Approximately 544,846 shares traded hands during mid-day trading, an increase of 107% from the average daily volume of 263,598 shares. The stock had previously closed at $5.20.

IMDZ has been the topic of several research reports. Jefferies Group LLC restated a “buy” rating and issued a $18.00 target price on shares of Immune Design Corp. in a report on Wednesday, June 28th. Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Tuesday, July 18th. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. ValuEngine upgraded shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Royal Bank Of Canada initiated coverage on shares of Immune Design Corp. in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Immune Design Corp. currently has a consensus rating of “Buy” and a consensus price target of $14.75.

The firm has a 50-day moving average of $9.97 and a 200 day moving average of $8.57. The firm’s market cap is $133.22 million.

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.11. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. On average, equities analysts forecast that Immune Design Corp. will post ($2.29) earnings per share for the current fiscal year.

In other Immune Design Corp. news, major shareholder Leo Guthart acquired 10,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were acquired at an average cost of $9.70 per share, with a total value of $97,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 20.70% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in shares of Immune Design Corp. by 123.3% in the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 8,418 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Immune Design Corp. in the 2nd quarter valued at $117,000. Alliancebernstein L.P. purchased a new stake in shares of Immune Design Corp. in the 2nd quarter valued at $118,000. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design Corp. in the 2nd quarter valued at $153,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Immune Design Corp. by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 1,600 shares during the last quarter. 51.46% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/immune-design-corp-imdz-shares-down-1-1/1650036.html.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.